Trade Basilea Pharma AG - BSLN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading Conditions
| Long position overnight fee | -0.0200% |
| Short position overnight fee | -0.0244% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | CHF |
| Margin | 20% |
| Stock exchange | Switzerland |
| Commission on trade | 0% |
*Information provided by Capital.com
Basilea Pharmaceutica AG ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 40.15 |
| Open* | 40.1 |
| Day's Range* | 38 - 38 |
| 1-Year Change* | -11.87% |
| Volume | N/A |
| Average Vol. (3m) | 0.77189 |
| 52 wk Range | N/A |
| Market Cap | 523.201 |
| P/E Ratio | N/A |
| Shares Outstanding | 11848700 |
| Revenue | 148.122 |
| EPS | -0.61297 |
| Dividend (Yield %) | N/A |
| Beta | 1.22322 |
| Next Earnings Date | Feb 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 16, 2022 | 40.15 | -2.50 | -5.86% | 42.65 | 42.90 | 40.05 |
| Aug 15, 2022 | 43.05 | -0.05 | -0.12% | 43.10 | 44.35 | 43.05 |
| Aug 12, 2022 | 43.25 | 0.85 | 2.00% | 42.40 | 43.80 | 42.40 |
| Aug 11, 2022 | 42.80 | 1.50 | 3.63% | 41.30 | 43.20 | 41.20 |
| Aug 10, 2022 | 41.70 | 0.85 | 2.08% | 40.85 | 41.75 | 40.05 |
| Aug 9, 2022 | 40.95 | -0.20 | -0.49% | 41.15 | 41.20 | 40.60 |
| Aug 8, 2022 | 41.35 | 0.15 | 0.36% | 41.20 | 41.50 | 40.80 |
| Aug 5, 2022 | 41.35 | 0.10 | 0.24% | 41.25 | 41.70 | 41.05 |
| Aug 4, 2022 | 41.50 | -1.05 | -2.47% | 42.55 | 42.55 | 41.40 |
| Aug 3, 2022 | 42.60 | 0.30 | 0.71% | 42.30 | 43.00 | 42.05 |
| Aug 2, 2022 | 42.50 | -0.95 | -2.19% | 43.45 | 43.50 | 42.15 |
| Jul 29, 2022 | 43.75 | -0.90 | -2.02% | 44.65 | 44.90 | 43.65 |
| Jul 28, 2022 | 44.50 | 0.60 | 1.37% | 43.90 | 44.70 | 43.15 |
| Jul 27, 2022 | 43.80 | 1.95 | 4.66% | 41.85 | 44.30 | 41.85 |
| Jul 26, 2022 | 42.35 | 1.55 | 3.80% | 40.80 | 43.00 | 40.55 |
| Jul 25, 2022 | 40.95 | 1.15 | 2.89% | 39.80 | 41.15 | 39.75 |
| Jul 22, 2022 | 39.85 | -0.15 | -0.37% | 40.00 | 40.70 | 39.75 |
| Jul 21, 2022 | 40.25 | -0.40 | -0.98% | 40.65 | 41.25 | 39.90 |
| Jul 20, 2022 | 40.85 | 0.00 | 0.00% | 40.85 | 41.35 | 40.45 |
| Jul 19, 2022 | 41.05 | 1.30 | 3.27% | 39.75 | 41.25 | 39.75 |
Basilea Pharma AG Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 65.984 | 101.521 | 132.555 | 134.381 | 127.629 | 148.122 |
| Revenue | 65.984 | 101.521 | 132.555 | 134.381 | 127.629 | 148.122 |
| Cost of Revenue, Total | 5.347 | 9.025 | 20.299 | 18.868 | 24.054 | 24.072 |
| Gross Profit | 60.637 | 92.496 | 112.256 | 115.513 | 103.575 | 124.05 |
| Total Operating Expense | 109.873 | 118.571 | 156.65 | 151.581 | 136.165 | 147.432 |
| Selling/General/Admin. Expenses, Total | 56.077 | 54.491 | 31.409 | 30.051 | 29.422 | 29.721 |
| Research & Development | 48.449 | 55.055 | 104.942 | 102.662 | 97.41 | 93.157 |
| Operating Income | -43.889 | -17.05 | -24.095 | -17.2 | -8.536 | 0.69 |
| Interest Income (Expense), Net Non-Operating | -6.379 | -6.653 | -6.528 | -6.396 | -7.485 | -8.085 |
| Other, Net | -0.686 | 4.677 | -0.537 | 1.214 | 1.354 | 0.601 |
| Net Income Before Taxes | -50.954 | -19.026 | -31.16 | -22.382 | -14.667 | -6.794 |
| Net Income After Taxes | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Net Income Before Extra. Items | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Net Income | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Income Available to Common Excl. Extra. Items | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Income Available to Common Incl. Extra. Items | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Diluted Net Income | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Diluted Weighted Average Shares | 10.1211 | 10.8459 | 10.8379 | 10.7557 | 10.2815 | 11.682 |
| Diluted EPS Excluding Extraordinary Items | -5.06732 | -1.78501 | -2.89281 | -2.08466 | -1.43189 | -0.58475 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | ||
| Diluted Normalized EPS | -5.06732 | -1.78501 | -2.89281 | -2.08466 | -2.36256 | -0.55793 |
| Unusual Expense (Income) | -14.721 | 0.482 |
| Dec 2019 | Jun 2020 | Dec 2020 | Jun 2021 | Dec 2021 | |
|---|---|---|---|---|---|
| Total revenue | 71.196 | 69.328 | 58.301 | 54.198 | 93.924 |
| Revenue | 71.196 | 69.328 | 58.301 | 54.198 | 93.924 |
| Cost of Revenue, Total | 9.498 | 13.085 | 10.969 | 13.525 | 10.547 |
| Gross Profit | 61.698 | 56.243 | 47.332 | 40.673 | 83.377 |
| Total Operating Expense | 75.202 | 56.514 | 79.651 | 69.808 | 77.624 |
| Selling/General/Admin. Expenses, Total | 13.881 | 14.449 | 14.973 | 14.339 | 15.382 |
| Research & Development | 51.823 | 43.939 | 53.471 | 41.689 | 51.468 |
| Operating Income | -4.006 | 12.814 | -21.35 | -15.61 | 16.3 |
| Interest Income (Expense), Net Non-Operating | -3.182 | -3.135 | -4.35 | -4.075 | -4.01 |
| Other, Net | 0.218 | 0.294 | 1.06 | -0.192 | 0.793 |
| Net Income Before Taxes | -6.97 | 9.973 | -24.64 | -19.877 | 13.083 |
| Net Income After Taxes | -6.991 | 9.941 | -24.663 | -19.891 | 13.06 |
| Net Income Before Extra. Items | -6.991 | 9.941 | -24.663 | -19.891 | 13.06 |
| Net Income | -6.991 | 9.941 | -24.663 | -19.891 | 13.06 |
| Income Available to Common Excl. Extra. Items | -6.991 | 9.941 | -24.663 | -19.891 | 13.06 |
| Income Available to Common Incl. Extra. Items | -6.991 | 9.941 | -24.663 | -19.891 | 13.06 |
| Diluted Net Income | -6.991 | 9.941 | -24.663 | -19.891 | 13.06 |
| Diluted Weighted Average Shares | 10.7596 | 10.8592 | 9.79463 | 11.5653 | 11.7986 |
| Diluted EPS Excluding Extraordinary Items | -0.64975 | 0.91545 | -2.51801 | -1.71988 | 1.10691 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Diluted Normalized EPS | -0.64975 | 0.02004 | -2.50222 | -1.70555 | 1.12612 |
| Unusual Expense (Income) | -14.959 | 0.238 | 0.255 | 0.227 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 268.494 | 292.976 | 274.738 | 184.86 | 223.528 | 241.066 |
| Cash and Short Term Investments | 239.03 | 260.724 | 223.034 | 129.024 | 161.772 | 148.7 |
| Cash | 33.4 | 50.1 | 37.4 | 52.5 | 50.1 | 53.7 |
| Cash & Equivalents | 205.63 | 150.624 | 135.634 | 56.524 | 10.649 | 0 |
| Short Term Investments | 0 | 60 | 50 | 20 | 101.023 | 95 |
| Total Receivables, Net | 7.409 | 15.026 | 35.593 | 30.315 | 37.901 | 65.7 |
| Accounts Receivable - Trade, Net | 2.492 | 4.955 | 3.757 | 6.242 | 8.71 | |
| Total Inventory | 14.931 | 15.32 | 14.411 | 18.569 | 21.192 | 22.783 |
| Other Current Assets, Total | 7.124 | 1.906 | 1.7 | 6.952 | 2.663 | 3.883 |
| Total Assets | 327.758 | 351.165 | 281.751 | 221.467 | 229.794 | 247.267 |
| Property/Plant/Equipment, Total - Net | 8.878 | 7.768 | 6.424 | 5.162 | 5.275 | 2.923 |
| Property/Plant/Equipment, Total - Gross | 45.178 | 45.1 | 45 | 44.2 | 29.348 | 17.505 |
| Accumulated Depreciation, Total | -36.3 | -37.3 | -38.6 | -39 | -24.1 | -14.6 |
| Intangibles, Net | 0.232 | 0.326 | 0.372 | 0.372 | 0.672 | 0.632 |
| Long Term Investments | 50 | 50 | 0 | 30 | 0 | |
| Other Long Term Assets, Total | 0.154 | 0.095 | 0.217 | 1.073 | 0.319 | 0.256 |
| Total Current Liabilities | 72.914 | 79.491 | 66.684 | 75.494 | 50.161 | 174.408 |
| Accounts Payable | 1.851 | 4.353 | 6.399 | 6.765 | 13.151 | 10.617 |
| Accrued Expenses | 14.9 | 19.6 | 26.7 | 29.3 | 29.052 | 33.453 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 56.163 | 55.538 | 33.585 | 39.429 | 7.958 | 6.833 |
| Total Liabilities | 362.758 | 392.605 | 348.438 | 314.427 | 331.84 | 305.874 |
| Total Long Term Debt | 195.466 | 196.224 | 196.982 | 197.74 | 239.668 | 94.544 |
| Long Term Debt | 195.466 | 196.224 | 196.982 | 197.74 | 239.668 | 94.544 |
| Other Liabilities, Total | 94.378 | 116.89 | 84.772 | 41.193 | 42.011 | 36.922 |
| Total Equity | -35 | -41.44 | -66.687 | -92.96 | -102.046 | -58.607 |
| Common Stock | 11.812 | 11.872 | 11.879 | 11.882 | 11.922 | 12.992 |
| Retained Earnings (Accumulated Deficit) | -20.94 | -33.108 | -55.05 | -74.324 | -33.95 | 6.577 |
| Treasury Stock - Common | -1 | -1 | -7.235 | -5.963 | -52.766 | -56.559 |
| Other Equity, Total | -24.872 | -19.204 | -16.281 | -24.555 | -27.252 | -21.617 |
| Total Liabilities & Shareholders’ Equity | 327.758 | 351.165 | 281.751 | 221.467 | 229.794 | 247.267 |
| Total Common Shares Outstanding | 10.812 | 10.8717 | 10.7447 | 10.7739 | 10.8673 | 11.842 |
| Note Receivable - Long Term | 2.39 | |||||
| Current Port. of LT Debt/Capital Leases | 123.505 |
| Dec 2019 | Jun 2020 | Dec 2020 | Jun 2021 | Dec 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 184.86 | 161.01 | 223.528 | 220.189 | 241.066 |
| Cash and Short Term Investments | 129.024 | 112.802 | 161.772 | 162.849 | 148.7 |
| Cash & Equivalents | 109.024 | 59.779 | 60.749 | 82.849 | 53.7 |
| Short Term Investments | 20 | 53.023 | 101.023 | 80 | 95 |
| Total Receivables, Net | 30.315 | 28.549 | 37.901 | 31.264 | 65.7 |
| Accounts Receivable - Trade, Net | 6.242 | 5.145 | 8.71 | 6.618 | |
| Total Inventory | 18.569 | 13.184 | 21.192 | 20.94 | 22.783 |
| Other Current Assets, Total | 6.952 | 6.475 | 2.663 | 5.136 | 3.883 |
| Total Assets | 221.467 | 197.055 | 229.794 | 227.176 | 247.267 |
| Property/Plant/Equipment, Total - Net | 5.162 | 1.683 | 5.275 | 3.767 | 2.923 |
| Property/Plant/Equipment, Total - Gross | 44.2 | 25.5 | 29.348 | 20.772 | 17.505 |
| Accumulated Depreciation, Total | -39 | -23.8 | -24.1 | -17 | -14.6 |
| Intangibles, Net | 0.372 | 0.589 | 0.672 | 0.467 | 0.632 |
| Long Term Investments | 30 | 30 | 0 | ||
| Other Long Term Assets, Total | 1.073 | 3.773 | 0.319 | 0.363 | 0.256 |
| Total Current Liabilities | 75.494 | 37.823 | 50.161 | 37.707 | 174.408 |
| Accounts Payable | 6.765 | 1.723 | 13.151 | 5.378 | 10.617 |
| Accrued Expenses | 23.4 | 22.4 | 29.052 | 25.235 | 33.453 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 45.329 | 11.9 | 7.958 | 7.094 | 6.833 |
| Total Liabilities | 314.427 | 276.631 | 331.84 | 305.928 | 305.874 |
| Total Long Term Debt | 197.74 | 198.118 | 239.668 | 227.869 | 94.544 |
| Long Term Debt | 197.74 | 198.118 | 239.668 | 227.869 | 94.544 |
| Other Liabilities, Total | 41.193 | 40.69 | 42.011 | 40.352 | 36.922 |
| Total Equity | -92.96 | -79.576 | -102.046 | -78.752 | -58.607 |
| Common Stock | 11.882 | 11.92 | 11.922 | 12.931 | 12.992 |
| Retained Earnings (Accumulated Deficit) | -74.324 | -60.48 | -33.95 | -10.401 | 6.577 |
| Treasury Stock - Common | -5.963 | -6.875 | -52.766 | -56.309 | -56.559 |
| Other Equity, Total | -24.555 | -24.141 | -27.252 | -24.973 | -21.617 |
| Total Liabilities & Shareholders’ Equity | 221.467 | 197.055 | 229.794 | 227.176 | 247.267 |
| Total Common Shares Outstanding | 10.7739 | 10.8008 | 10.8673 | 11.7932 | 11.842 |
| Current Port. of LT Debt/Capital Leases | 1.8 | 123.505 | |||
| Note Receivable - Long Term | 2.39 | 2.39 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -51.287 | -19.36 | -31.352 | -22.422 | -14.722 | -6.831 |
| Cash From Operating Activities | -75.003 | 19.014 | -79.21 | -63.836 | -54.134 | -32.02 |
| Cash From Operating Activities | 2.319 | 1.991 | 1.852 | 1.639 | 1.19 | 0.754 |
| Non-Cash Items | 8.796 | 5.374 | 7.009 | 3.806 | -9.84 | 5.844 |
| Changes in Working Capital | -34.831 | 31.009 | -56.719 | -46.859 | -30.762 | -31.787 |
| Cash From Investing Activities | 1.211 | -60.94 | 59.391 | -0.404 | -34.963 | 3.575 |
| Capital Expenditures | -0.431 | -0.945 | -0.609 | -0.404 | -2.265 | -0.86 |
| Other Investing Cash Flow Items, Total | 1.642 | -59.995 | 60 | 0 | -32.698 | 4.435 |
| Cash From Financing Activities | 0.411 | 2.631 | -5.986 | 1.309 | 45.067 | 16.64 |
| Issuance (Retirement) of Stock, Net | 0.411 | 2.631 | -5.986 | 1.309 | 4.809 | 39.852 |
| Issuance (Retirement) of Debt, Net | 0 | 43.451 | -23.212 | |||
| Foreign Exchange Effects | -0.653 | 0.989 | -1.011 | 0.067 | -0.758 | 0.501 |
| Net Change in Cash | -74.034 | -38.306 | -26.816 | -62.864 | -44.788 | -11.304 |
| Cash Taxes Paid | 0.283 | 0.413 | 0.141 | 0.026 | 0.035 | |
| Cash Interest Paid | 5.756 | 5.795 | 5.666 | 4.843 | 7.074 | |
| Financing Cash Flow Items | -3.193 |
| Dec 2019 | Jun 2020 | Dec 2020 | Jun 2021 | Dec 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -22.422 | 9.941 | -14.722 | -19.891 | -6.831 |
| Cash From Operating Activities | -63.836 | -33.171 | -54.134 | -27.151 | -32.02 |
| Cash From Operating Activities | 1.639 | 0.817 | 1.19 | 0.399 | 0.754 |
| Non-Cash Items | 3.806 | -12.657 | -9.84 | 2.705 | 5.844 |
| Changes in Working Capital | -46.859 | -31.272 | -30.762 | -10.364 | -31.787 |
| Cash From Investing Activities | -0.404 | -16.231 | -34.963 | 19.113 | 3.575 |
| Capital Expenditures | -0.404 | -0.871 | -2.265 | -0.307 | -0.86 |
| Other Investing Cash Flow Items, Total | 0 | -15.36 | -32.698 | 19.42 | 4.435 |
| Cash From Financing Activities | 1.309 | 1.097 | 45.067 | 26.195 | 16.64 |
| Issuance (Retirement) of Stock, Net | 1.309 | 1.097 | 4.809 | 38.82 | 39.852 |
| Foreign Exchange Effects | 0.067 | -1.093 | -0.758 | 0.249 | 0.501 |
| Net Change in Cash | -62.864 | -49.398 | -44.788 | 18.406 | -11.304 |
| Financing Cash Flow Items | -3.193 | ||||
| Issuance (Retirement) of Debt, Net | 43.451 | -12.625 | -23.212 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 427000+
Traders
71000+
Active clients monthly
$46000000+
Monthly investing volume
$17000000+
Try now Withdrawn each month
Basilea Company profile
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
Grenzacherstrasse 487
BASEL
BASEL-STADT 4058
CH
Income statement
News
Darktrace takeover: Thoma Bravo buyout firm’s DARK offer timing and details in full
Will others join Thoma Bravo and bid for Darktrace?
10:12, 17 August 2022
Nifty 50 today: overall bullish despite choppy conditions, say analysts
India 50 could continue its bullish outlook unless there are major domestic developments
02:47, 17 August 2022
Berkshire Hathaway ATVI stock buy: Is Buffett betting on Microsoft’s Activision Blizzard acquisition going ahead?
Berkshire Hathaway is gobbling up shares of Activision Blizzard in a display of confidence that Microsoft will will close the deal to purchase Activision Blizzard
00:00, 17 August 2022
Crypto market wrap; Celsius coin keeps falling, Acala burns
Hodlnaut seeks protection from creditors
22:42, 16 August 2022
Crypto market wrap: Acala stablecoin collapses, altcoin prices dip
Investors show no mercy for beleaguered Celsius coin
16:02, 16 August 2022People Also Watch
US Natural Gas Spot
9.44 Price
| Long position overnight fee | -0.0007% |
| Short position overnight fee | -0.0126% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 0.005 |
Trade now
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
